Swiss Re’s Gilead Sciences GILD Stock Holding History

Swiss Re’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Buy	2,083 +1,832	+730%	+$241K	0.02%	85
2026 Q1	$35K	Hold	251	–	–	0.21%	61
2025 Q4	$30.8K	Buy	+251	New	+$30.5K	﹤0.01%	71

Other funds holding GILD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Swiss Re's GILD Position: Q2 2026 in Review

Swiss Re increased its Gilead Sciences (GILD) stake by 730% in Q2 2026, buying an estimated $241K and bringing the position to 2,083 shares worth $263K. The position accounts for 0.02% of the portfolio, ranked #85.

Swiss Re first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

Swiss Re held 2,083 shares of Gilead Sciences worth $263K as of Q2 2026.
Swiss Re bought 1,832 Gilead Sciences shares in Q2 2026, an estimated $241K.
Gilead Sciences made up 0.02% of Swiss Re's portfolio in Q2 2026, its #85 holding.
Swiss Re first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Swiss Re's 13F filing for Q2 2026, filed 11 Aug 2026.